Characterization and extending the use of the humanized mouse model for psoriasis for pre-clinical testing of new drug.

Recruiting

• Conditions: flaking disease; psoriasis; 10003816; 10014982

• Registration Number: NL-OMON34915
• Lead Sponsor: TNO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use localcorticosteriods or ointments to prevent dry skin (see appendix 2).;Healthy controls: Adults (m/f) who do not have skin condition (as recognized by physisian or dermatologist)

Exclusion Criteria

Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexaat, cyclosporin A,anti-TNF treatments). Gender or age of the adults are not a exclusion criteria.(see appendix 2);Healthy controls: are not to undergo treatment with drugs like prednisolon and cyclosporine.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Effect on the psoriatic process is tested by histology and immuno-histochemical<br /><br>techniques in the transplanted biopsies. Main read-out epidermal thickness.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Additionally, several markers which are know to be associated with lesional<br /><br>psoriasis skin wil be evaluated. This allows us to make a better comparison<br /><br>between the human situation and the processes seen in the model.</p><br>